This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, M A
Right arrow Articles by Heifetz, C L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, M A
Right arrow Articles by Heifetz, C L

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 January; 35(1): 141-146

In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.

M A Cohen, M D Huband, G B Mailloux, S L Yoder, G E Roland, J M Domagala and C L Heifetz

Department of Experimental Therapy, Parke-Davis Pharmaceutical Research Division, Ann Arbor, Michigan 48105.

ABSTRACT

PD 131628 is a new aminopyrrolidine-substituted fluorocyclopropyl naphthyridine quinolone which possesses high in vitro activity against a wide spectrum of bacterial species. The MICs for greater than or equal to 90% of strains were 0.125 to 0.25 microgram/ml for staphylococci, Streptococcus pyogenes, and S. pneumoniae; 0.5 micrograms/ml for S. agalactiae and Enterococcus faecalis; 0.125 micrograms/ml for members of the family Enterobacteriaceae and Acinetobacter spp.; 0.5 micrograms/ml for Pseudomonas aeruginosa; and less than or equal to 0.03 micrograms/ml for Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, and Neisseria gonorrhoeae. In these in vitro comparisons with ciprofloxacin, PD 131628 is more active against gram-positive organisms, approximately equivalent against gram-negative organisms, and, like most other quinolones, relatively inactive against gram-negative anaerobes. In most instances, the in vitro potency of PD 131628 exceeded those of widely used compounds: ciprofloxacin, imipenem, ampicillin, penicillin G, oxacillin, cefazolin, ceftazidime, cefoxitin, cefsulodin, aztreonam, piperacillin, amikacin, spectinomycin, doxycycline, erythromycin, metronidazole, and vancomycin.


Antimicrob Agents Chemother. 1991 January; 35(1): 141-146




This article has been cited by other articles:

  • Paker, G. E., Graham, J. A., Rauch, A. M., Collins, J. J. (1994). Cefuroxime Axetil in the Treatment of Sinusitis: A Review. Arch Fam Med 3: 165-175 [Abstract]